Please ensure Javascript is enabled for purposes of website accessibility

Why Rockwell Medical, Inc. Shares Are Crashing Today

By Todd Campbell – Mar 1, 2016 at 1:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Poor sales for its recently launched Triceric have investors heading for the exit.

What: Shares of Rockwell Medical (RMTI -4.19%) were tumbling 31% at 12:30 p.m. EST Tuesday due to reporting fourth quarter financial results, after the bell Monday, that disappointed investors.

RMTI Total Return Price Chart

RMTI Total Return Price data by YCharts

So what: In its first few months on the market, sales of Rockwell Medical's newly launched drug, Triferic, an iron replacement therapy for chronic kidney disease patients, failed to win traction.

In the past, iron replacement therapy has been done in dialysis centers using IV infusion, a method that can lead to patient complications, and because of those risks, industry watchers had been hopeful Triferic could win away market share.

Unfortunately, that market share has been hard to come by.

According to the company's 10-K filing with the SEC, the company only sold an anemic $200,000 worth of the drug in the fourth quarter and as a result, its total revenue was $14.1 million in Q4, down $300,000 from a year ago.

Even worse, the company's gross profit slipped by 3% year over year to $2.1 million in the fourth quarter, and the combination of poor sales and rising expenses led to Rockwell Medical losing $5.8 million in the three-month span.

Full year results weren't much better.

Rockwell Medical's revenue only inched up 2.1% to $55.4 million and its loss totaled $14.4 million in 2015.

Now what: Rockwell Medical's CEO Robert Chioini attempted to put a positive spin on the performance, referring to the year as "exceptional," but his optimistic assessment shouldn't be surprising. In his Q4, 2014 financial press release he used the word "exceptional" to describe his company's performance, which included a tepid 3.5% revenue increase and in the company's Q4, 2013 earnings press release he described Triferic's phase 3 clinical data as "exceptional" too.

Overall, until real-world uptake of this drug proves Triferic is worthy of Chioini's accolades, I don't see a compelling reason to buy shares in Rockwell Medical, even at these lower prices.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Rockwell Medical Stock Quote
Rockwell Medical
$1.03 (-4.19%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.